Difficulty: Medium
Average Score: 75%
Practice
Favorable characteristics of pramipexole as a dopamine agonist for treatment of parkinsonism in a 72-year-old man would include which of the following?
Correct answer
B
Rationale
In the context of CNS pharmacology and the treatment of parkinsonism, the favorable characteristics of pramipexole as a dopamine agonist for a 72-year-old man include its favorable bioavailability. Pramipexole has good oral bioavailability, which means that a significant portion of the drug reaches systemic circulation intact after oral administration. This is crucial for ensuring the drug's effectiveness in the treatment of parkinsonism in elderly patients who may have difficulty with swallowing or compliance with multiple doses.
Option A, extensive metabolism, would not be a favorable characteristic for pramipexole in this case. Extensive metabolism may lead to variations in drug levels and efficacy, especially in elderly patients who may have altered drug metabolism due to age-related changes.
Option C, hepatic excretion, is not ideal for pramipexole as it may increase the risk of drug interactions and potential liver toxicity, especially in older individuals who may already have compromised liver function.
Option D, short half-life, would not be advantageous for pramipexole as a dopamine agonist used in the treatment of parkinsonism. A longer half-life allows for less frequent dosing, which can improve patient compliance and reduce the risk of fluctuations in symptom control.
In an educational context, understanding the pharmacokinetic properties of drugs used in the treatment of neurodegenerative disorders like parkinsonism is essential for healthcare providers to make informed decisions regarding drug selection, dosing, and monitoring. Knowledge of drug characteristics such as bioavailability, metabolism, excretion, and half-life is crucial in optimizing therapeutic outcomes and minimizing adverse effects, particularly in vulnerable populations like the elderly.
Option A, extensive metabolism, would not be a favorable characteristic for pramipexole in this case. Extensive metabolism may lead to variations in drug levels and efficacy, especially in elderly patients who may have altered drug metabolism due to age-related changes.
Option C, hepatic excretion, is not ideal for pramipexole as it may increase the risk of drug interactions and potential liver toxicity, especially in older individuals who may already have compromised liver function.
Option D, short half-life, would not be advantageous for pramipexole as a dopamine agonist used in the treatment of parkinsonism. A longer half-life allows for less frequent dosing, which can improve patient compliance and reduce the risk of fluctuations in symptom control.
In an educational context, understanding the pharmacokinetic properties of drugs used in the treatment of neurodegenerative disorders like parkinsonism is essential for healthcare providers to make informed decisions regarding drug selection, dosing, and monitoring. Knowledge of drug characteristics such as bioavailability, metabolism, excretion, and half-life is crucial in optimizing therapeutic outcomes and minimizing adverse effects, particularly in vulnerable populations like the elderly.